1. Prevalence of High-risk Nonavalent Vaccine-type Human Papillomavirus Infection Among Unvaccinated, Sexually Active Asian Female Adolescents With and Without Perinatally Acquired HIV Infection.
- Author
-
Sricharoenchai S, Kerr SJ, Gatechompol S, Hansudewechakul R, Dang HLD, Tran DNH, Teeratakulpisarn N, Chalermchockcharoenkit A, Achalapong J, Teeraananchai S, Singtoroj T, Phanuphak N, Sohn AH, and Chokephaibulkit K
- Subjects
- Adolescent, Antibodies, Viral blood, Cohort Studies, Female, HIV Infections virology, Humans, Papillomaviridae classification, Papillomaviridae isolation & purification, Papillomavirus Vaccines administration & dosage, Prevalence, Sexually Transmitted Diseases blood, Sexually Transmitted Diseases epidemiology, Sexually Transmitted Diseases virology, Thailand epidemiology, Vietnam epidemiology, Young Adult, HIV Infections epidemiology, Infectious Disease Transmission, Vertical, Papillomaviridae genetics, Papillomavirus Infections epidemiology, Sexual Behavior statistics & numerical data
- Abstract
Background: We studied the prevalence of 7, high-risk human papillomavirus (HPV) types in the nonavalent vaccine (HRVT-7: HPV 16, 18, 31, 33, 45, 52, 58) among vaccine-naïve, sexually active Asian female adolescents with and without perinatally acquired HIV infection (PHIV)., Methods: PHIV female adolescents 12-24 years of age and HIV-uninfected controls matched by age and number of lifetime sex partners were enrolled in a 3-year observational cohort study in Thailand and Vietnam. Samples from the oral cavity, anus, cervix and vagina were collected for HRVT-7 HPV genotyping, and serum collected for HPV 16 and 18 antibody testing. Baseline data were analyzed using multivariable logistic regression., Results: We included 93 PHIV (median CD4 593 cells/mm, 62% with HIV RNA suppression) and 99 HIV-uninfected adolescents (median lifetime sex partners 2). The overall prevalence of HRVT-7 infection was 53% in PHIV and 49% in HIV-uninfected adolescents (P = 0.66). Cervical HRVT-7 DNA was detected more frequently in PHIV than HIV-uninfected adolescents (37% vs. 23%, P = 0.04). Overall, more lifetime partners [≥3 vs. 1; odds ratio (OR) 2.99 (1.38-6.51), P = 0.02] and having other sexually transmitted infections [OR 3.30 (1.51-7.21), P = 0.003] increased the risk of HRVT-7 infection and/or positive HPV 16/18 antibodies; while detectable HIV RNA [OR 2.78 (1.05-7.36), P = 0.04] increased the risk among PHIV adolescents., Conclusions: Half of sexually active Asian female adolescents, regardless of HIV infection, had already acquired HRVT-7 infection. This underscores the need for earlier access to HPV vaccine in the region.
- Published
- 2020
- Full Text
- View/download PDF